2018
Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors
Strosberg D, Schneider EB, Onesti J, Saunders N, Konda B, Shah M, Dillhoff M, Schmidt CR, Shirley LA. Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors. Annals Of Surgical Oncology 2018, 25: 3613-3620. PMID: 30182331, DOI: 10.1245/s10434-018-6741-x.Peer-Reviewed Original ResearchConceptsRepeat transarterial chemoembolizationMetastatic neuroendocrine tumorsTransarterial chemoembolizationPancreastatin levelsNeuroendocrine tumorsOverall survivalPrognostic impactImproved overall survivalProgressive liver diseaseFirst transarterial chemoembolizationWorse overall survivalUseful prognostic indicatorLong-term survivalPg/mLConclusionsFor patientsPost TACECarcinoid syndromeTACE treatmentLiver metastasesPatient demographicsImproved survivalLiver diseasePoor outcomePrognostic indicatorResultsA total
2016
Predictors of improved survival for patients with retroperitoneal sarcoma
Giuliano K, Nagarajan N, Canner JK, Wolfgang CL, Bivalacqua T, Terezakis S, Herman J, Schneider EB, Ahuja N. Predictors of improved survival for patients with retroperitoneal sarcoma. Surgery 2016, 160: 1628-1635. PMID: 27495850, DOI: 10.1016/j.surg.2016.05.041.Peer-Reviewed Original ResearchConceptsRetroperitoneal sarcomaMultivariable survival analysisSurvival analysisRetroperitoneal sarcoma patientsEnd Results (SEER) databaseOperative resectionImproved survivalLymph nodesSurvival benefitDistant metastasisHistologic typeResults databaseSarcoma patientsRare tumorCancer DatabaseLonger survivalPatientsSarcomaSurvivalParametric survival functionsLocal extensionFurther studiesHigh rateResectionRecurrence